<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">25154911</PMID>
      <DateCompleted>
        <Year>2015</Year>
        <Month>01</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2014</Year>
        <Month>11</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1749-6632</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>1329</Volume>
            <PubDate>
              <Year>2014</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Annals of the New York Academy of Sciences</Title>
          <ISOAbbreviation>Ann N Y Acad Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis.</ArticleTitle>
        <Pagination>
          <StartPage>33</StartPage>
          <EndPage>44</EndPage>
          <MedlinePgn>33-44</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/nyas.12512</ELocationID>
        <Abstract>
          <AbstractText>Walking impairment is a clinical hallmark of multiple sclerosis (MS). Dalfampridine-ER, an extended-release formulation of dalfampridine (also known by its chemical name, 4-aminopyridine, and its international nonproprietary name, fampridine), was developed to maintain drug plasma levels within a narrow therapeutic window, and assessed for its ability to improve walking in MS. The putative mechanism of action of dalfampridine-ER is restoration of axonal conduction via blockade of the potassium channels that become exposed during axonal demyelination. Two pivotal phase III clinical trials demonstrated that dalfampridine-ER 10-mg tablets administered twice daily improved walking speed and patient-reported perceptions of walking in some patients. Dalfampridine-ER was generally well tolerated, and, at the approved dose, risk of seizure was neither elevated relative to placebo nor higher than the rate in the MS population. Dalfampridine-ER (AMPYRA®) was approved in the United States for the treatment of walking in patients with MS as demonstrated by an increase in walking speed. The use of the dalfampridine-ER is contraindicated in patients with a history of seizure. It is the first pharmacologic therapy for this indication and has been incorporated into clinical management of MS.</AbstractText>
          <CopyrightInformation>© 2014 The Authors. Annals of the New York Academy of Sciences published by Wiley Periodicals Inc. on behalf of The New York Academy of Sciences.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Blight</LastName>
            <ForeName>Andrew R</ForeName>
            <Initials>AR</Initials>
            <AffiliationInfo>
              <Affiliation>Acorda Therapeutics, Ardsley, New York.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Henney</LastName>
            <ForeName>Herbert R</ForeName>
            <Initials>HR</Initials>
            <Suffix>3rd</Suffix>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cohen</LastName>
            <ForeName>Ron</ForeName>
            <Initials>R</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>08</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Ann N Y Acad Sci</MedlineTA>
        <NlmUniqueID>7506858</NlmUniqueID>
        <ISSNLinking>0077-8923</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D026902">Potassium Channel Blockers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>BH3B64OKL9</RegistryNumber>
          <NameOfSubstance UI="D015761">4-Aminopyridine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015761" MajorTopicYN="N">4-Aminopyridine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
          <QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName>
          <QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D026902" MajorTopicYN="N">Potassium Channel Blockers</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016138" MajorTopicYN="N">Walking</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">4-aminopyridine</Keyword>
        <Keyword MajorTopicYN="N">dalfampridine</Keyword>
        <Keyword MajorTopicYN="N">fampridine</Keyword>
        <Keyword MajorTopicYN="N">multiple sclerosis</Keyword>
        <Keyword MajorTopicYN="N">walking</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>8</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>8</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2015</Year>
          <Month>1</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">25154911</ArticleId>
        <ArticleId IdType="doi">10.1111/nyas.12512</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
